Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous golimumab randomized-withdrawal trial in pediatric polyarticular course juvenile idiopathic arthritis
2009-015019-42Phase 3Completed
- Sponsor
- Janssen Biologics B.V.
- Start
- Aug 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in juvenile idiopathic arthritis (JIA) comparing Golimumab continuation with Placebo withdrawal control (2 arms). Primary endpoint: ACR30 response at Week 16 with no disease flare through Week 48. Started Aug 2010; status: completed.
02
Drugs
golimumab
03
Conditions
juvenile idiopathic arthritis (JIA)
Beyond the preview
Go deeper on 2009-015019-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-015019-42.